Title
A systematic review of pharmacogenetic guided opioid therapy for pain.
Authors
Sneha Jethwa
Contact:
University of Cambridge
Contributions
Dr Kenneth Langlands
Rationale
Genetic polymorphisms have been shown to have a role in the variability in response to analgesics. Clinical Pharmacogenetics Implementation Consortium (CPIC) has issued guidelines that support pharmacogenetic testing for opioid therapy, including the CYP2D6, OPRM1, and COMT genes (Crews et al., 2021). There is a need to determine if pharmacogenetic-guided opioid prescribing leads to improved clinical outcomes using data from clinical trials and whether healthcare providers could benefit from using these tests as part of routine care.
Objectives
1) Determine if pharmacogenetic guided opioid prescribing improves clinical outcomes.
2) Determine if pharmacogenetic tests reduce adverse effects when prescribing opioid therapy.
3) Identify gaps in research and provide recommendations for future research.
Method
A systematic literature review was carried in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines 2020. The following databases were searched: Embase, MEDLINE, Cochrane Central Register of Controlled Trials and Web of Science. The search results were reported in accordance with the PRISMA-S checklist